SPPI Spectrum Pharmaceuticals Inc.

11.58
0  0%
Previous Close 11.58
Open 11.47
Price To Book 4.32
Market Cap 1238057079
Shares 106,913,392
Volume 879,309
Short Ratio
Av. Daily Volume 1,194,260

SEC filingsSee all SEC filings

  1. 8-K - Current report 181175004
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181169939
  3. 8-K - Current report 181169625
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181005314
  5. 8-K - Current report 181005012

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 abstract noted ORR 58%; PFS 5.6 months.
Poziotinib
Non-small cell lung cancer (NSCLC) with exon 20 insertion mutation in EGFR or HER2
Phase 2 initiation announced March 30, 2017 with preliminary data released October 18, 2017 - ORR 73%.
Poziotinib
Non-small cell lung cancer (NSCLC)
CRL received October 9, 2009. Approved April 29, 2011.
FUSILEV
Colorectal cancer
CRL received July 5, 2009.
ZEVALIN
Non-Hodgkin’s lymphoma
CRL October 23 2015. Approved March 15 2016.
EVOMELA (melphalan) for Injection
Conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma
Phase 2 initiated March 2016. Ongoing.
Poziotinib
Breast cancer
Failed to meet primary endpoint in Phase 3 trial - Apr 2012. PDUFA date December 11 2016. Advisory Committee Meeting September 14 2016 voted 14 - 0 against approval. CRL issued November 17, 2016. New Phase 3 trial initiation announced August 14, 2017.
QAPZOLA - Apaziquone
Bladder cancer
Phase 3 ADVANCE trial met primary endpoint of non-inferiority in comparison to pegfilgrastim. Additional Phase 3 RECOVER trial also met primary endpoint. BLA to be filed 4Q 2018.
SPI-2012 (ROLONTIS)
Chemotherapy-Induced Neutropenia
Approved July 7, 2014.
Belinostat
Peripheral T-Cell Lymphoma cancer
Phase 2 data at ASH December 2018.
Leucovorin
Peripheral T-Cell Lymphoma cancer

Latest News

  1. Is Spectrum Pharmaceuticals, Inc. (SPPI) Going to Burn These Hedge Funds?
  2. Here's Why Spectrum Pharmaceuticals Rose 21.5% in November
  3. Spectrum Pharma (SPPI) Down 3.7% Since Last Earnings Report: Can It Rebound?
  4. Edited Transcript of SPPI earnings conference call or presentation 8-Nov-18 9:30pm GMT
  5. Spectrum Pharmaceuticals Announces Results from the RECOVER Phase 3 Study of ROLONTIS® (eflapegrastim) at the 2018 SABCS Annual Meeting
  6. Report: Exploring Fundamental Drivers Behind CVS Health, TransCanada, Nektar Therapeutics, LendingTree, Spectrum Pharmaceuticals, and TripAdvisor — New Horizons, Emerging Trends, and Upcoming Developments
  7. Spectrum Pharmaceuticals Announces Positive Results from Phase 2 Trial Evaluating Use of Oral Leucovorin to Potentially Mitigate Mucositis in Patients Treated with FOLOTYN® (pralatrexate)
  8. Spectrum Pharmaceuticals Highlights Three Posters at the 60th Annual Meeting of the American Society of Hematology
  9. Spectrum Pharmaceuticals Appoints Dr. Jeffrey Vacirca to its Board of Directors
  10. Spectrum (SPPI) Earnings and Sales Beat Estimates in Q3
  11. Ligand (LGND) Beats on Q3 Earnings & Revenues, Raises View
  12. Today's Research Reports on Trending Tickers: Omeros and Spectrum Pharmaceuticals
  13. Spectrum Pharmaceuticals (SPPI) Reports Q3 Loss, Tops Revenue Estimates
  14. Spectrum Pharma: 3Q Earnings Snapshot
  15. Spectrum Pharmaceuticals Reports Third Quarter 2018 Pipeline Update and Financial Results
  16. Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2018 London Healthcare Conference on November 14
  17. Veracyte Stock Witnesses Solid Growth after Its Q3 Results
  18. Spectrum Pharmaceuticals Announces Third Quarter 2018 Financial Results Teleconference and Webcast
  19. Spectrum Pharmaceuticals (SPPI) Q3 Earnings Preview: What's Shaping Up?
  20. Analysis: Positioning to Benefit within Spectrum Pharmaceuticals, Carnival, Cadence Design, Tandem Diabetes Care, Rigel Pharmaceuticals, and Regeneron Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results